Cambridge Antibody Technology
E422486
Cambridge Antibody Technology was a pioneering UK biotechnology company best known for developing human monoclonal antibody technologies that led to blockbuster therapeutic drugs.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Cambridge Antibody Technology canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T4221593 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Cambridge Antibody Technology Context triple: [Cambridge life sciences ecosystem, hasKeyCompany, Cambridge Antibody Technology]
-
A.
Genmab
Genmab is a Danish biotechnology company specializing in the development of antibody-based cancer therapies.
-
B.
Genentech
Genentech is a pioneering American biotechnology company known for developing groundbreaking therapies and being one of the first firms to apply genetic engineering to medicine.
-
C.
Lonza
Lonza is a global Swiss-based life sciences company specializing in pharmaceutical, biotech, and nutrition products and services, particularly in contract development and manufacturing.
-
D.
Eurofins Scientific
Eurofins Scientific is a global leader in bioanalytical testing services, specializing in food, environmental, pharmaceutical, and clinical laboratory analysis.
-
E.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Cambridge Antibody Technology Target entity description: Cambridge Antibody Technology was a pioneering UK biotechnology company best known for developing human monoclonal antibody technologies that led to blockbuster therapeutic drugs.
-
A.
Genmab
Genmab is a Danish biotechnology company specializing in the development of antibody-based cancer therapies.
-
B.
Genentech
Genentech is a pioneering American biotechnology company known for developing groundbreaking therapies and being one of the first firms to apply genetic engineering to medicine.
-
C.
Lonza
Lonza is a global Swiss-based life sciences company specializing in pharmaceutical, biotech, and nutrition products and services, particularly in contract development and manufacturing.
-
D.
Eurofins Scientific
Eurofins Scientific is a global leader in bioanalytical testing services, specializing in food, environmental, pharmaceutical, and clinical laboratory analysis.
-
E.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
biopharmaceutical company
ⓘ
biotechnology company ⓘ research organization ⓘ |
| acquiredBy | AstraZeneca ⓘ |
| collaboratedWith |
Abbott Laboratories
ⓘ
AstraZeneca ⓘ Daiichi Sankyo ⓘ Human Genome Sciences ⓘ |
| country | United Kingdom ⓘ |
| developedTechnologyUsedIn |
Humira
ⓘ
adalimumab ⓘ benralizumab ⓘ other therapeutic antibodies ⓘ |
| field |
drug discovery
ⓘ
monoclonal antibodies ⓘ therapeutic antibodies ⓘ |
| focusesOn |
autoimmune disease therapies
ⓘ
inflammatory disease therapies ⓘ oncology-related antibodies ⓘ |
| foundedBy |
David Chiswell
ⓘ
Greg Winter ⓘ |
| hasAchievement |
contributed to first fully human monoclonal antibody approved for clinical use
ⓘ
helped establish fully human antibody drugs as a major therapeutic class ⓘ played key role in commercialization of adalimumab ⓘ |
| hasKeyPerson |
David Chiswell
ⓘ
Greg Winter ⓘ Ian Tomlinson ⓘ John McCafferty ⓘ Michael Neuberger ⓘ |
| hasReputation |
leader in phage display antibody technology
ⓘ
pioneer in therapeutic antibody discovery ⓘ |
| hasResearchArea |
immunology
ⓘ
molecular biology ⓘ protein engineering ⓘ |
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| knownFor |
collaboration with major pharmaceutical companies
ⓘ
contribution to blockbuster therapeutic antibody drugs ⓘ development of human monoclonal antibody technologies ⓘ |
| locatedIn |
Cambridgeshire
ⓘ
linked to:
Cambridgeshire, England
|
| locatedNear |
Cambridge
ⓘ
linked to:
CAMBRIDGE
|
| specializesIn |
antibody engineering
ⓘ
human monoclonal antibody technology ⓘ phage display technology ⓘ |
| successorOrganization |
AstraZeneca biologics division
ⓘ
linked to:
AstraZeneca
MedImmune ⓘ |
| usedMethod |
antibody library construction
ⓘ
in vitro antibody evolution ⓘ phage display selection of antibodies ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Cambridge Antibody Technology Description of subject: Cambridge Antibody Technology was a pioneering UK biotechnology company best known for developing human monoclonal antibody technologies that led to blockbuster therapeutic drugs.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.